Kornimate/medical-research-clean huggingface dataset:
assessment of cognitive function after surgery in two types of anesthesia in patients operated for breast cancer

Conditions: Patients With Breast Cancer and Breast Surgery Requiring

Summary: the emergence of cognitive disorders after surgery under general anesthesia (ga) is the second leading cause of patient complaints (after dental debris caused by intubation techniques). these cognitive disorders can range from simple reversible confusion (26%) with postoperative cognitive dysfunction without actual recovery (10%). the hypnosedation is an ancient technique of anesthesia expanding its effects on cognitive function remain to this day unknown, but appear promising.

for twenty years, hypnosedation is offered to patients who underwent surgery as an alternative to other anesthetic techniques (general anesthesia and locoregional), in some european and anglo-saxon hospitals for specific surgical indications (surgery area). it is commonly used in some hospitals. the hypnosedation is little used in oncology the hypnosedation is a hypnosis technique suitable for anesthesia, namely the one associated with intravenous conscious sedation and local anesthesia hypnosis. this derived from medical hypnosis ericksoniene technique is divided into three stages: 1. induction 2. deepening trance 3. déhypnotisation. this technique is currently being validated and used at national and international level, in fact it is based on 500 references and appears in the national nomenclature of the common classification of medical procedures in the code anrp 001, states: hypnosis referred to analgesic.

Eligibility criteria:
inclusion criteria: * female, over 18 and under 80 years * diagnosis of breast cancer established (pathology) * life expectancy greater than 6 months * surgery of breast lumpectomy with or without lymph node dissection, mastectomy with or without lymph node dissection, dissection isolated * asa 1 (healthy patient) or 2 (patient with moderate to high function) according to the classification of the american society of anesthesiologist, * affiliation to a social security scheme, * information on the study, signed informed consent exclusion criteria: * presence of major psychiatric disorders or psychotic behavior addiction, evaluated by neuropsychologist at the first preoperative consultation, through the test mini (mini\> 4 positive responses for each module) * presence of neurological disorders known untreated or evaluated by neuropsychologist at the first preoperative consultation, with the mmse test (mmse \<24) * patient treated morphine orally for 3 months or more * patient is pregnant or nursing, or of childbearing potential and not using adequate contraception, * patient included in another clinical study * inability to undergo medical monitoring study for geographical, social or psychological * patient deprived of liberty and most subject to a measure of legal protection or unable to consent

Keywords: patients with breast cancer and breast surgery requiring
evaluation of dna methylation signatures for the diagnosis and management of thyroid nodules

Conditions: Thyroid Gland Carcinoma

Summary: this clinical trial evaluates deoxyribonucleic acid (dna) methylation signatures in diagnosing and managing thyroid nodules. the purpose of this research is to develop a new test for thyroid cancer. this test will use needle biopsies (small collections of tissue with a needle) from the thyroid to determine whether the participant has a malignant (cancer) or benign (not showing cancer) thyroid tumor. the information learned from this trial may help develop a more accurate test so that patients do not have unnecessary surgeries for nodules that are thought to be suspicious but are actually benign.

primary objective: i. to evaluate the effect of diagnostic dna methylation signatures (ddms-2) results (positive predictive value \[ppv\], negative predictive value \[npv\], sensitivity and specificity) on physician decision-making for clinical management of 800 indeterminate thyroid nodules. secondary objectives: i. to determine sensitivity and specificity, ppv, npv of ddms-2 with 1450 needle biopsies including 800 needle biopsies with indeterminate cytopathology. ii. compare the diagnostic accuracy between ddms-2 and two currently used diagnostic approaches based on genetic alterations and gene expression within the same prospective cohort of 800 indeterminate needle biopsies. outline: patients undergo needle biopsy for collection of tissue samples. tissue samples are analyzed using ddms-2. patients' medical records are also reviewed.

Eligibility criteria:
inclusion criteria: * patients without impaired decision-making capacity and who are undergoing needle biopsies for thyroid nodule diagnosis * over the age of 18 * any gender, race and ethnicity * patients must provide informed consent prior to use of their tissues and clinical data exclusion criteria: * children are excluded from the study, since the biology of children thyroid nodules is different from adults
the role of the upper colliculus in the idiopathic blepharospasm

Conditions: Blepharospasm, Benign Essential

Summary: this pilot study aims at investigating the role of superior colliculus in patients with idiopathic blepharospasm (bsp) de novo, compared to healthy subjects.

the objective of the study is to investigate the function of the superior colliculus (sc) related to visual stimulation by means of fmri (functional magnetic resonance imaging) in patients with idiopathic bsp compared to healthy subjects. the hypothesis is that sc function is impaired in bsp (role of biomarker of sc).

Eligibility criteria:
inclusion criteria: * non treated idiopathic blepharospasm * age: 30- 70 years exclusion criteria: * under the following treatments: botulin toxin, anticholinergic, benzodiazepines, baclofen, beta- and alpha-blockers collyrium * no mri contraindication

Keywords: superior colliculus fmri
a phase i/ii study of gmx1777 in combination with temozolomide for the treatment of metastatic melanoma

Conditions: Metastatic Melanoma

Summary: obatoclax mesylate (gmx1777) is a water-soluble, intravenously-administered pro-drug of gmx1778. gmx1777 is rapidly converted to gmx1778 in vivo. gmx1778 has potent anti-tumor activity against a variety of cell lines and models from different tumor origins.

gmx1777 will be administered as 3-hour infusions in combination with temozolomide taken orally for the treatment of metastatic melanoma. gmx1777 infusion will be given on either day 1, days 1 and 3, or days 1,3, and 5 every 4 weeks. temozolomide will be administered on 5 consecutive days every 4 weeks. no investigational or commercial agents or therapies other than those described may be administered with the intent to treat the patient's malignancy.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed metastatic melanoma * up to 1 prior chemotherapy regimen allowed; prior immunotherapy allowed * normal organ and marrow function * willing to submit to blood sampling for planned pk/pd analyses * ability of understand and willingness to sign a written informed consent exclusion criteria: * no other investigational or commercial agents or therapies * prior exposure to gmx1777, gmx1778 or chs828 * patients with uncontrolled, intercurrent illness * pregnant or breastfeeding women
purtox (botulinum toxin type a) for the treatment of adult onset spasmodic torticollis/cervical dystonia

Conditions: Spasmodic Torticollis

Summary: the safety and efficacy of mentor purified toxin, botulinum toxin type a, purified neurotoxin, injected intramuscularly into the neck, is being evaluated as a treatment for painful and non-painful spasmodic torticollis/cervical dystonia. it is hypothesized that treatment will decrease symptom severity and will not have any significant side effects.


Eligibility criteria:
inclusion criteria: * diagnosis of torticollis with noticeable symptoms for at least 6 months * total twstrs score greater or equal to 20, twstrs severity score greater than or equal to 10 and twstrs disability score greater than or equal to 3 (must meet all 3 criteria) exclusion criteria: * diagnosis of isolated anterocollis * concurrent myopathic disease, myotonic dystrophy (or other form of muscular dystrophy), myasthenia gravis * currently receiving aminoglycoside antibiotic therapy, curare-like drugs, quinidine, succinylcholine, polymixins, anticholinesterases, magnesium sulfate, or lincosamides * any illness that is considered by the investigator to make the subject an inappropriate candidate * cervical spine injury within 18 months or head and neck surgery within 6 months prior to screening * pre-existing dysphagia * history of active autoimmune disease * exposure to botulinum toxin based pharmaceutical within 3 months prior to screening * history of primary non-response or secondary resistance with prior exposure to botulinum based pharmaceuticals * history of chemotherapy/radiation for malignant disease within 24 months * any investigational drug/device during the 30 days prior to screening

Keywords: torticollis cervical dystonia
leukotriene d4 nasal provocation test in allergic rhinitis

Conditions: Allergic Rhinitis; Asthma

Summary: leukotrienes play critical roles in the inflammatory process in allergic rhinitis and bronchial asthma, therefore, anti-leukotriene therapy is part of treatment for asthma. however, not all allergic rhinitis accompanied with or without asthma treated with anti-leukotriene were effective. so it is critical to develop a method to identify the response subgroup. in this study, it is assumed that nasal physiological responsiveness to leukotriene nasal provocation test (npt) is able to gain evidence on the effect of leukotriene on the development of allergic rhinitis and asthma, and is helpful to the use of anti-leukotriene agent. the purpose of the study is to establish the methodology and diagnostic value of leukotriene d4 (ltd4) nasal provocation.

nasal provocation test induced by ltd4 will be conducted by measuring nasal airway resistance and airway symptoms in a stepwise concentration of ltd4 by nasal spray. inflammation biomarkers, such as eosinophilic granulocyte in sputum and nasal lavage, fractional exhaled nitric oxide(feno), and lung function before and after nasal provocation will be studied to explore the impact of ltd4 nasal provocation test on airway inflammation.

Eligibility criteria:
inclusion criteria: * patients with allergic rhinitis accompanied with or without asthma * positive skin prick test (spt) * had no acute upper or lower airway infection 2 weeks prior to study * no oral or nasal anti-histamines * no leukotriene receptor antagonists for 1 week * no oral or nasal and inhaled corticosteroids for 2 weeks exclusion criteria: * smokers * a past confirmed history of chronic respiratory disease other than asthma * other severe systemic diseases (myocardial infarction, malignant tumor, etc.) * under immunotherapy * unable to complete the test or had limited understanding * pregnancy

Keywords: leukotriene d4 allergic rhinitis nasal airway resistance nasal provocation test nasal hyperreactivity airway inflammation asthma
controlled study of mk-0431/ono-5435 in patients with type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to determine the safety and efficacy of mk-0431/ono-5435 in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and glimepiride as monotherapy


Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes mellitus on diet/exercise therapy and glimepiride as monotherapy exclusion criteria: * patients with type 1 diabetes mellitus

Keywords: mk-0431 ono-5435 type 2 diabetes mellitus
feasibility evaluation of cpap in the treatment of obstructive sleep apnea synchrone in the acute phase of stroke

Conditions: Obstructive Sleep Apnea Syndrome

Summary: this project is focused on the treatment of obstructive sleep apnea in the acute phase of stroke. stroke is a frequent pathology with a high morbidity and mortality rate. although it has now been proved that obstructive sleep apnea syndrome (osas) is a risk factor of stroke, on the other hand, there is evidence that 50 to 70% of patients in the acute phase of stroke have obstructive sleep apnea (osa) based on an apnea-hypopnea index (ahi) of ≥ 10. osa is associated with worse functional outcomes and higher mortality in the post-stroke period. profound hemodynamic fluctuations and hypoxia generated by sleep apnea are likely to aggravate cerebral ischemia, particularly in the acute phase of stroke in the potentially reversible ischemic penumbra. continuous positive airway pressure (cpap) is the primary treatment for obstructive sleep apnea. yet, to our knowledge, there have been very few studies aimed at demonstrating the value of cpap in the treatment of obstructive sleep apnea in the acute phase of stroke. only one randomised trial has provided the means to document neurological improvement at mid term (1 month) in a targeted population. before undertaking a comparative study evaluating the efficacy of cpap in the acute phase of ischemic stroke, it is worth evaluating the feasibility and tolerance of introducing cpap at the very early stage of ischemic stroke. therefore, the purpose of our study is to evaluate the feasibility of cpap in the treatment of osa in the acute phase of ischemic stroke.


Eligibility criteria:
inclusion criteria: * - clinical presentation of ischemic stroke confirmed by imaging (ct or mri brain scan) * less than 24 hours from onset of symptoms * admitted to the neurovascular unit of the emergency hospitalisation department of 'hôpital nord' of the university hospital of saint-étienne * presenting obstructive sleep apnea syndrome (defined as an apnea-hypopnea index (ahi) of ≥ 10 and \> 50% of obstructive events) * written consent of patient exclusion criteria: * concussion (coma glasgow score \<12) * comprehension aphasia * uncontrollable confusion and agitation * history of dementia * history of ischemic stroke with neurological damage * history of hemorrhagic stroke * history of epilepsy * cerebrospinal fluid leak, recent cranial surgery or head injury * serious bullous lung disease * hypoxic pulmonary disease * pleurisy or pneumothorax requiring draining * respiratory distress requiring mechanical ventilation * oxygen therapy prior to stroke * non-invasive ventilation therapy prior to stroke * hypotension * dehydration * hypersalivation * vomiting * pregnancy, parturients, breast feeding * absence of consent

Keywords: obstructive sleep apnea syndrome acute stroke apnea-hypopnea index (ahi)
efficacy and safety of premixed insulin treatment in patients with type 2 diabetes mellitus

Conditions: Type 2 Diabetes

Summary: the aim of the study is to investigate the efficacy and safety of premixed insulin treatment in patients with type 2 diabetes mellitus using professional and personal flash glucose mornitoring.

professional and personal flash glucose mornitoring will be used in patients with type 2 diabetes who are treated with premixed insulin. the frequency of hypogycemia and the blood glucose control will be analyzed by flash glucose mornitoring once a month for 3 months and doctors will adjust the hypoglycemia treatment according to the results every month. hba1c, glycemic variation, beta-cell function and androgen levels will be measured.

Eligibility criteria:
inclusion criteria: 1. participate voluntarily and sign the subject informed consent before the test. 2. for patients with type 2 diabetes who met who1999 diagnostic criteria, subcutaneous injection with premix insulin bid/tid, single drug and/or combination of oral hypoglycemic drugs, the treatment regimen was stable for more than 2 months. 3. no acute complications such as diabetic ketoacidosis and diabetic hyperosmolar syndrome. 4. subjects are able and willing to undergo fgm examination, diet and exercise regularly. exclusion criteria: 1. patients treated with glp-1 agonist in the last 3 months 2. patients who are allergic to insulin. 3. impaired liver and renal function, alt 2.5 times higher than the upper limit of normal value;serum creatinine was 1.3 times higher than the upper limit of normal. 4. a history of drug abuse and alcohol dependence within the past 5 years. 5. used systemic hormone therapy in recent 3 months. 6. patients with poor compliance and irregular diet and exercise. 7. patients with infection and stress within four weeks. 8. patients who cannot tolerate flash glucose mornitoring. 9. patients who are pregnant, nursing or or preparing to become pregnant. 10. any other apparent condition or comorption as determined by the investigator, such as severe heart and lung disease, endocrine disease, neurological disease, tumor disease, other pancreatic disease, history of mental illness.
a blood based diagnostic test for coeliac disease

Conditions: Coeliac Disease; Non Coeliac Gluten Sensitivity

Summary: persons with coeliac disease treated with a gluten free diet will be asked to give blood for a new diagnostic blood test. in this test investigators will use multimerized hla bound to different gliadin-peptides (tetramer) and with the help of a flow-cytometer identify (along with other relevant t-cell-markers) gluten specific t-cells. investigators believe that these cells will be present in persons with coeliac disease regardless of gluten-intake. investigators will compare their findings with two control groups; persons on a gluten free diet where celiac disease is excluded (gluten sensitive group) and persons on a gluten containing diet (healthy control group). in the initial and main study investigators will look at hla dq2.5 individuals, which comprise \>90% of all persons with coeliac disease.


Eligibility criteria:
inclusion criteria: * hla dq2.5 positives in primary blinded study (other hla-types ie dq8 and dq2.2 in later unblinded study) * in gluten free group: diagnosis must be confirmed by duodenal biopsy done after sufficient time on gluten containing diet and participant must have followed a glutenfree diet since. exclusion criteria: * drugs that influence the immune system used last three months * infected with hepatitis b, c or hiv * pregnant

Keywords: gluten tetramer
tapping test and the archimedean spiral for the differential diagnosis of tremor. machine learning approach

Conditions: Tremor; Essential Tremor; Parkinson Disease

Summary: in clinical practice, it is sometimes difficult to establish whether a patient's tremor is due to parkinson's disease or essential tremor. the distinction is crucial as the health implications differ significantly between the two conditions. therefore, the present study aims to develop a diagnostic method based on machine learning techniques to help differentiate whether a patient's tremor is due to one condition or the other. to achieve this, 110 patients with tremor, correctly diagnosed with either parkinson's disease or essential tremor, will participate. they will undergo two diagnostic tests (tapping test and archimedean spiral) to capture data that can be processed using machine learning techniques.


Eligibility criteria:
inclusion criteria: * possibility to collaborate in the necessary evaluations. * follow-up in the specialized consultation of movement disorders at the neurology service of hospital sant camil-consorci sanitari alt penedes i garraf. * legal capacity to provide informed consent. * signature of informed consent for study inclusion, either by the participant themselves or by their legal representative. * participant with criteria from group 1 or 2: group 1: * confirmed diagnosis of tremor due to parkinson's disease, clinically established, based on the diagnostic criteria of the movement disorders society, and additionally: * tremor associated with bradykinesia of any duration. * confirmatory clinical diagnosis of tremor due to parkinson's disease (stages 1 to 2 of hoehn and yahr) by the neurologist responsible for the participant's follow-up. group 2: * confirmed diagnosis of essential tremor, based on the criteria of the movement disorders society, and additionally: * positional tremor plus kinetic and/or resting tremor with follow-up in outpatient neurology consultations for at least 3 years without a change in diagnosis. * absence of bradykinesia. exclusion criteria: * patients undergoing treatment with antipsychotics or antidepressants. * patients with parkinson's disease and dyskinesias. * patients undergoing treatment with dopaminergic agonists or primidone. * tremor of such severity that it prevents continuous tracing, at the investigator's discretion. * cognitive or affective pathology that limits the ability to collaborate with the study procedures. * participation in another clinical study involving an intervention, procedure, or visit frequency that is incompatible with the present study. * participants diagnosed with any of the following conditions: alcoholism of sufficient intensity to influence handwriting or cause neuropathy, at the investigator's discretion. peripheral neuropathy of any cause. dystonias. previous stroke.

Keywords: tremor essential tremor parkinson disease diagnosis, differential machine learning